Is Thx Pharma SA halal to invest in?

According to Musaffa's Shariah screening methodology, Thx Pharma SA (ALTHX.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Thx Pharma SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Thx Pharma SA using these criteria to determine its compliance status.

Can Muslims buy shares of Thx Pharma SA?

Muslim investors may consider investing in Thx Pharma SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Thx Pharma SA classified as NOT HALAL?

Musaffa determines the Shariah status of Thx Pharma SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Thx Pharma SA updated?

The Shariah compliance status of Thx Pharma SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Thx Pharma SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Thx Pharma SA?

You can check the latest Shariah compliance status of Thx Pharma SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Thx Pharma SA ALTHX.PA

€3.51 €0.01 (0.14%) 1D

Last Updated: May 15, 12:00 AM·XPAR

ALTHX.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 26, 2025

Report Source: 2024 Annual Report

Thx Pharma SA. Stock Analysis ALTHX.PA

France Health Care Micro Cap Report: 2024 Annual

THX Pharma engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The firm is an antisense oligonucleotide platform for the identification and characterization of therapy drug candidates co-constructed with laboratories in the field of neurological diseases. The first drug, TX01 for the disease of Niemann-Pick type C and Gaucher’s disease. The second drug, Batten-1, aims at the form juvenile of Batten disease and could be the first therapy considered in this form. The company has marketed its drugs notably in Europe and also in the United States, Canada and Australia.

Key Statistics of Thx Pharma SA (ALTHX.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€3.47€3.73

Today's Open

€3.51

Volume

134.13K

P/E Ratio (TTM)

52 Week Range

€0.74€5.10

Market Cap

48.80M

Avg. Volume

32.75K

Dividend Yield

Financial Metrics & Statements of Thx Pharma SA (ALTHX.PA)

FAQ's for Thx Pharma SA (ALTHX.PA)

According to Musaffa’s Shariah screening methodology, Thx Pharma SA (ALTHX.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.